License Agreements and Asset Purchase Agreements (Details) - USD ($) $ in Thousands	1 Months Ended						12 Months Ended
	Oct. 31, 2022	Aug. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jul. 31, 2022	Feb. 28, 2019
License Agreements and Asset Purchase Agreements
Cost of product sold							$ 121,236	$ 83,481	$ 55,518
Accrued Sales Based Trademark and Royalties							40,419	25,367
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics
License Agreements and Asset Purchase Agreements
Consideration transferred		$ 3,500
Payment for intellectual property upon preclinical milestones		1,750
Payment for intellectual property upon developmental milestones		19,000
Payment for intellectual property upon regulatory milestones		44,000
Payment for intellectual property upon sales milestones		$ 110,000
Bioprojet
License Agreements and Asset Purchase Agreements
Licensing agreement milestone fees						$ 2,000
License agreement milestone payments paid					$ 75,000	2,000
License agreement, additional milestone payment due						102,000
Accrued Sales Based Trademark and Royalties							40,419	25,367
Bioprojet | Upon Acceptance by FDA of Pitolisant's
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due											$ 50,000
License agreement, upfront non-refundable licensing fees paid	$ 30,000
License agreement, maximum additional milestone payment due										$ 155,000
Bioprojet | Upon Acceptance by FDA of Pitolisant's | Research and development expense
License Agreements and Asset Purchase Agreements
License agreement, upfront non-refundable licensing fees paid								30,000
Bioprojet | Upon FDA Approval of WAKIX
License Agreements and Asset Purchase Agreements
License agreement, milestone payment due						77,000
Licensing agreement milestone fees						$ 2,000
License agreement milestone payments paid			$ 100,000	$ 2,000
Bioprojet | Sales-based, trademark and tiered royalties
License Agreements and Asset Purchase Agreements
Cost of product sold							111,685	$ 77,107	$ 50,957
Bioprojet | United States
License Agreements and Asset Purchase Agreements
Amount of Aggregate Net Sales Attaining							500,000
Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX
License Agreements and Asset Purchase Agreements
Final payment paid							$ 40,000